Form D · Other Technology
Kamau Therapeutics, Inc.
South San Francisco, CA · CIK 0002071165
Offering snapshot reported Jun 3, 2025 · SEC filing
- Reported sold
- $5M Offering amount: $10M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 19, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 3, 2025 | Initial | $4,999,997 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-547903
Source: Form D, filed Jun 3, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Valentin Barsan | Director, Executive |
| Ness Bermingham | Director |
| Raymond Kelleher | Director |
| Matthew Porteus | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
220 E. Grand Avenue
South San Francisco, CA, 94080
South San Francisco, CA, 94080